Uttar Pradesh plans 200-acre bio-pharma park in Pilibhit
A Terai district better known for forests and farming is being lined up for vaccines and gene therapy plants. Uttar Pradesh is carving a 200-acre bio-pharma park inside a 951.79-acre industrial area at Bhara Pachpeda in Pilibhit’s Amaria tehsil. The park will push units that make vaccines, insulin, gene therapies and monoclonal antibodies. Read it for industrial location, UPSIDA and India’s drug-manufacturing push beyond big cities.
- Bio-pharma park
- 200 acres
- Full industrial area
- 951.79 acres, Bhara Pachpeda, Amaria
- Industrial plots
- 575.79 acres
- Distance
- About 36 km from Pilibhit city; 100 km from Bareilly
Pilibhit bio-pharma park: what happened?
Pilibhit sits in the Terai, near Nepal. Planners now want it to host high-end biological drugs, not only farms and forests.
- UPSIDA (Uttar Pradesh State Industrial Development Authority) is developing a modern industrial area on 951.79 acres at Bhara Pachpeda in Amaria tehsil, Pilibhit.
- Of this, 200 acres are earmarked for a dedicated bio-pharma park aimed at vaccines, insulin, gene therapies and monoclonal antibodies (lab-made proteins that target disease).
- Land mix: 575.79 acres for industrial plots, 60.98 acres for common facilities, 109.23 acres for green areas and 96.20 acres for roads; 14 plots are already open for allotment.
- Plans also talk of a biotechnology institute, skill centres and an incubation hub so local youth can train and start firms.
- Officials say the site is about 36 km from Pilibhit city, 100 km from Bareilly and about 300 km from Lucknow and Delhi, with rail links and nearness to the Nepal border for trade.
Why put a drug park in the Terai?
Bio-pharma means medicines made from living cells, not only chemical tablets. India already leads in vaccines and generic drugs; States now race to host the next wave of biological plants.
Pilibhit’s climate and location are being sold as strengths for storage and formulation work. Spreading industry beyond Noida and Lucknow is also a stated State goal.
UPSIDA builds and allots industrial estates across Uttar Pradesh. A Promote Pharma Council expert, G.N. Singh, has publicly explained the Pilibhit land split.
How the 951.79 acres are planned
| Use | Acres |
|---|---|
| Industrial plots | 575.79 |
| Bio-pharma park (inside the estate) | 200 |
| Green areas | 109.23 |
| Roads | 96.20 |
| Common facilities | 60.98 |
Which policies and ideas apply?
- Industrial policy of Uttar Pradesh and UPSIDA estate rules govern allotment and infrastructure.
- Drugs and Cosmetics Act, 1940, and CDSCO (Central Drugs Standard Control Organisation) licence rules for manufacturing.
- National Pharmaceutical Policy and Make in India / PLI-style push for domestic drug capacity (context, not a new PLI package for this park).
- Biotechnology is a concurrent concern of the Centre and States; States compete with land, skills and power.
Why does the Pilibhit bio-pharma park matter?
| Angle | What to note |
|---|---|
| Industry | Moves high-value manufacturing into a smaller Terai district. |
| Jobs | Skill centres and plants can employ local youth. |
| Health security | More Indian capacity for vaccines and biological drugs. |
| Location | Rail, roads and the Nepal border shape trade routes. |
What are the problems with the Pilibhit bio-pharma park?
- A park on paper needs power, cold chain, water and trained staff before plants come.
- Environmental clearances and waste rules for bio-plants are strict and can delay allotment.
- Competition from established pharma clusters in other States remains strong.
- Nearness to forests and the Terai ecology needs careful pollution control.
What should be done next on the Pilibhit bio-pharma park?
- Allot plots with clear timelines for utilities.
- Tie the skill centre to actual factory hiring.
- Publish environmental and biomedical waste plans early.
- Market the park to vaccine and biologics firms with one-window clearances.
What can Prelims ask on the Pilibhit bio-pharma park?
Prelims probability: Expect a location or scheme question on UPSIDA industrial areas, or on what bio-pharma products (vaccines, insulin, monoclonal antibodies, gene therapy) a dedicated park is meant to host.
- UPSIDA builds State industrial areas in Uttar Pradesh.
- Bio-pharma focus products: vaccines, insulin, gene therapy, monoclonal antibodies.
- Site: Bhara Pachpeda, Amaria tehsil, Pilibhit; 200 of 951.79 acres.
- CDSCO regulates drug manufacturing licences.
- Industrial location factors: raw materials, labour, power, transport, markets.
How to write about the Pilibhit bio-pharma park in Mains
Practice question (UP PCS GS-V / GS-III, 8 marks, 125 words): Spreading pharmaceutical manufacturing beyond metro belts can balance regional growth. Discuss with reference to the proposed Pilibhit bio-pharma park.
- Intro: 200-acre park inside 951.79-acre estate.
- Why Terai / Pilibhit: location and State strategy.
- What bio-pharma needs: skills, cold chain, regulation.
- Risks: environment, delays, competition.
- Conclusion: land plus skills equals real jobs.
Ready lines for your answer
- Industry that only hugs metros leaves talent and districts behind.
- A bio-pharma park succeeds only when skills and cold chain arrive with the plots.
Quotable data point200-acre bio-pharma park inside 951.79 acres at Bhara Pachpeda, Amaria, Pilibhit.
Photo: ArmouredCyborg, CC BY-SA 4.0, via Wikimedia Commons
Exam angle
Prelims: UPSIDA, bio-pharma products, industrial location. · Mains GS-III: manufacturing, biotech and regional development.
Practice MCQs
Original practice questions (not PYQs).
Consider the following statements about the proposed Pilibhit industrial project:
1. UPSIDA is developing an industrial area of about 951.79 acres at Bhara Pachpeda in Amaria tehsil.
2. Within that estate, 200 acres are earmarked for a bio-pharma park.
3. The park is planned mainly for coal washeries and steel rerolling mills.
Which of the statements given above is/are correct?
Answer (a) & explanation
Statements 1 and 2 are correct. Statement 3 is wrong: the park targets vaccines, insulin, gene therapies and monoclonal antibodies.
Monoclonal antibodies, mentioned in the Pilibhit bio-pharma plan, are best described as:
Answer (b) & explanation
Monoclonal antibodies are laboratory-made proteins that bind to a chosen target; they are a key class of modern biological medicines.
Questions students ask about this
Where will the Pilibhit bio-pharma park come up?
On 200 acres inside a 951.79-acre UPSIDA industrial area at Bhara Pachpeda in Amaria tehsil, Pilibhit.
What will units in the park make?
Modern biological medicines such as vaccines, insulin, gene therapies and monoclonal antibodies.
What is UPSIDA?
The Uttar Pradesh State Industrial Development Authority, which develops and allots industrial estates in the State.
How far is the site from major cities?
About 36 km from Pilibhit city, 100 km from Bareilly and about 300 km from Lucknow and Delhi.
Is this only factories, or training too?
Plans also include a biotechnology institute, skill development and an incubation centre for startups.